Monopar Therapeutics Inc Share Price Today: Live Updates & Key Insights

Monopar Therapeutics Inc share price today is $55.67, up -5.9%. The stock opened at $58.02 against the previous close of $58.67, with an intraday high of $58.26 and low of $55.42.

Monopar Therapeutics Inc Share Price Chart

Monopar Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Monopar Therapeutics Inc Share Price Performance

$55.67 -0.059(-5.9%) MNPR at 23 Mar 2026 02:18 PM Biotechnology
Lowest Today 55.42
Highest Today 58.26
Today’s Open 58.02
Prev. Close 58.67
52 Week High 105.00
52 Week Low 26.06
Day’s Range: Low 55.42 High 58.26
52-Week Range: Low 26.06 High 105.00
1 day return -
1 Week return -10.38
1 month return -0.98
3 month return -22.91
6 month return -13.26
1 year return +49.25
3 year return +1857.8
5 year return +695.53
10 year return -

Monopar Therapeutics Inc Institutional Holdings

HHG PLC 19.26

RA Capital Management, LLC 9.98

Adage Capital Partners Gp LLC 9.57

Saturn V Capital Management LLC 4.87

Vanguard Group Inc 4.40

ADAR1 Capital Management LLC 3.50

Wellington Management Company LLP 3.38

Siren, L.L.C. 3.18

BlackRock Inc 3.05

Deerfield Management Co 2.55

Vanguard Total Stock Mkt Idx Inv 2.51

TCG Crossover Management, LLC 2.29

Janus Henderson Hrzn Biotec E2 USD 1.93

iShares Russell 2000 ETF 1.69

Polar Capital Holdings PLC 1.58

Polar Capital Biotech S Inc 1.50

Geode Capital Management, LLC 1.48

Vivo Capital, LLC 1.35

Millennium Management LLC 1.15

State Street Corp 1.08

Fidelity Small Cap Index 0.67

Vanguard Institutional Extnd Mkt Idx Tr 0.64

Alyeska Investment Group, L.P. 0.60

iShares Russell 2000 Growth ETF 0.57

Driehaus Capital Management LLC 0.50

Neuberger Berman Group LLC 0.49

Balyasny Asset Management LLC 0.48

State St Russell Sm/Mid Cp® Indx SL Cl I 0.42

BNY Mellon Sm/Md Cp Gr I 0.41

DWS ESG Biotech LC 0.37

iShares Core S&P Total US Stock Mkt ETF 0.35

Vanguard Russell 2000 ETF 0.33

Fidelity Extended Market Index 0.31

Neuberger Small Cap Growth Inv 0.30

Vanguard US Momentum Factor ETF 0.26

Neuberger Berman Small Cap Growth 0.26

Wellington CIF Small Cap 2000 0.23

State St Russell Sm Cap® Indx SL Cl I 0.23

Neuberger Berman Small Cap Growth Tr II 0.18

iShares Micro-Cap ETF 0.18

Monopar Therapeutics Inc Market Status

Strong Buy: 2

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Monopar Therapeutics Inc Fundamentals

Market Cap 368.95 M

PB Ratio 2.7697

PE Ratio 0.0

Enterprise Value 248.46 M

Total Assets 60.29 M

Volume 266041

Monopar Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:122400 0.1M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:122400 0.1M, FY19:null 0.0M

Annual Net worth FY23:-9484619 -9.5M, FY22:-10494399 -10.5M, FY21:-9079200 -9.1M, FY20:-6222671 -6.2M, FY19:-4125987 -4.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-3437601 -3.4M, Q2/2025:-2453526 -2.5M, Q1/2025:-2624972 -2.6M, Q3/2024:-1304276000 -1304.3M, Q2/2024:-1715309 -1.7M

About Monopar Therapeutics Inc & investment objective

Company Information Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Organisation Biotechnology

Employees 14

Industry Biotechnology

CEO Dr. Chandler D. Robinson M.B.A., M.D., M.Sc.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Monopar Therapeutics Inc FAQs

What is the share price of Monopar Therapeutics Inc today?

The current share price of Monopar Therapeutics Inc is $55.67.

Can I buy Monopar Therapeutics Inc shares in India?

Yes, Indian investors can buy Monopar Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Monopar Therapeutics Inc shares in India?

You can easily invest in Monopar Therapeutics Inc shares from India by:

Can I buy fractional shares of Monopar Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Monopar Therapeutics Inc?

Monopar Therapeutics Inc has a market cap of $368.95 M.

In which sector does Monopar Therapeutics Inc belong?

Monopar Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Monopar Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Monopar Therapeutics Inc?

The PE ratio of Monopar Therapeutics Inc is N/A and the PB ratio is 2.77.